Earnings Flash (JCAP) Jefferson Capital, Inc. Posts Q1 Adjusted EPS $0.73 per Share, vs. FactSet Est of $0.70

Jefferson Capital, Inc. / DE (JCAP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 jcap-20260813xex99d1.htm EX-99.1 ​ Exhibit 99.1 ​ Jefferson Capital Reports Second Quarter 2026 Results ​ Collections Grow 18% to $300.9 Million and Deployments grow 21% to $152.2 Million Estimated Remaining Collections (“ERC”) up 18% to $3.4 Billion Pre-tax Income of $

Reuters reports that U.S. President Donald Trump ordered the Navy to drop the electromagnetic aircraft carrier launch system and return to steam catapults, via a national security memorandum. The change would require removing the system on Gerald R. Ford-class carriers and is expected to cost billions. Huntington Ingalls is the primary contractor building the Ford class, according to the White House.

Northrop Grumman (NYSE:NOC) received a $158.8 million contract modification from the U.S. Department of War, according to the agency. The award under contract W58RGZ-26-C-0009 covers definitization, with work at Rolling Meadows, Illinois. Completion is estimated Aug. 13, 2026, and $158.831 million in fiscal 2026 funds were obligated.

Brookfield Corp. said it can manage financing risks tied to a planned US$500 billion partnership to fund AI chip purchases, alongside Nvidia and other financial institutions. Brookfield CFO Nick Goodman cited risk controls like cash-flow contracts. Brookfield reported Q2 distributable earnings of US$1.4 billion (61 cents/share) and profit of US$703 million (14 cents/share).

Akari Therapeutics reported a Q2 2026 net loss of $4.8M, up from $1.9M a year earlier, and said it ended June 30, 2026 with $7.7M cash. The company raised about $8.6M gross proceeds (about $8.0M net) via private placement and warrant exercises. Akari is advancing AKTX-101 toward a planned mid-2027 Phase 1 start.

Gossamer Bio reported Q2 2026 net income of $16.9M and cash, cash equivalents and marketable securities of $57.0M as of June 30, 2026, citing non-operating gains from debt extinguishment. Revenue from collaborators was $9.2M. The company said it plans to submit an NDA for seralutinib in PAH in Sept 2026 and received FDA Pre-NDA Type B minutes. Shareholders approved a convertible note exchange and a potential reverse stock split.